SAB Biotherapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
SABS Nasdaq 2836 www.sab.bio

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for SAB Biotherapeutics, Inc.

SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting - May 29th, 2026 6:00 am
Emergent BioSolutions Inc. (EBS) Gains Attention as ACAM2000 Receives Broader Public Health Authorization - May 20th, 2026 2:43 pm
We Think SAB Biotherapeutics (NASDAQ:SABS) Needs To Drive Business Growth Carefully - May 15th, 2026 5:32 am
SAB Biotherapeutics Inc (SABS) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Rising ... - May 12th, 2026 5:03 pm
SAB Biotherapeutics Q1 Earnings Call Highlights - May 12th, 2026 11:14 am
SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights - May 12th, 2026 5:30 am
SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET - May 5th, 2026 6:30 am
Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142 - Apr 29th, 2026 5:35 am
SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026 - Apr 22nd, 2026 5:00 am
SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress - Apr 15th, 2026 6:00 am
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants - Mar 19th, 2026 2:01 pm
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants - Mar 17th, 2026 8:46 pm
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - Mar 17th, 2026 2:01 pm
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes - Mar 10th, 2026 5:31 am
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights - Mar 9th, 2026 3:16 pm
SAB BIO to Participate in Upcoming Investor Conferences - Mar 2nd, 2026 7:00 am
SAB Biotherapeutics Pitches SAB-142 as Redosable Human ATG for Type 1 Diabetes at Oppenheimer Conf - Mar 1st, 2026 12:43 pm
SAB Biotherapeutics Spotlights SAB-142 Phase 2b Plan in Type 1 Diabetes at Guggenheim Summit 2026 - Feb 14th, 2026 11:05 pm
Analysts Predict Up to 400% Spike for These 2 ‘Strong Buy’ Penny Stocks - Jan 25th, 2026 4:05 am
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director - Jan 7th, 2026 6:00 am